Global Respiratory Syncytial Virus Market, By Drug Type (Synagis, Virazole, Palivizumab, Riba Tab and Others), By Dosage Form (Oral, Injectable, Inhaler and Others), By Treatment Type (Immune Prophylaxis, Supportive Care and Antiviral Medications), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies and Clinics), By Region(North America, Europe, Asia Pacific, South America, Middle East & Africa), Competition, Forecast & Opportunities to 2027
The respiratory syncytial virus market is expected to reach revenue of US$ 4,202.6 million by 2027, growing at a CAGR of 14.9% over the forecast period 2022-2027. Read More
We Are Trusted By These Great Companies!
Published On: 02-Aug-2021 | Format: | Report ID: AA0821085